4. Systemic, biologic, other radioisotope, embolization therapies within ≤12 weeks prior to study enrollment. [Patients on long acting somatostatin analogs such as octreotide LAR® are eligible but this must be stopped 6 weeks prior to starting 177Lu and switched to short acting prior to 177Lu therapy. See section 4.8.1].